| 摘要 |
<p>An isolated nucleic acid molecule consists of genomic DNA encoding a MAGE-B gene consisting of: a) nucleotides 3266-7979 of SEQ ID NO:15; b) nucleotides 23546-25194 of SEQ ID NO:15; c) nucleotides 29748-31474 of SEQ ID NO:15; d) nucleotides 29748-31827 of SEQ ID NO:15 or e) nucleotides 31403-39691 of SEQ ID NO:15. An isolated nucleic acid molecule encodes a MAGE-B1 variant, consisting of, in 5' to 3' order: f) nucleotides 31403-31474, 33958-34062, 35057-35139 and 38088-39691 of SEQ ID NO:15; g) nucleotides 31403-31474, 33958-34062, and 38088-39691 of SEQ ID NO:15; h) nucleotides 35057-35139 and 38088-39691 of SEQ ID NO:15 or i) nucleotides 33958-34062 and 38088-39691 of SEQ ID NO:15. An isolated nucleic acid molecule having a nucleotide sequence as set forth in SEQ ID NO:12; SEQ ID NO:16; SEQ ID NO:17 or SEQ ID NO:18 is useful as an oligonucleotide primer. A method for screening for possibility of a testicular seminoma, non-small cell lung carcinoma, melanoma-1 breast cancer, sarcoma or leukemia in a sample, comprises: contacting the sample with at least one nucleic acid molecule which hybridizes to mRNA corresponding to an MAGE-Xp gene, and then determining hybridization as a determination of possible presence of testicular seminoma, non-small cell lung carcinoma, melanoma, breast cancer, sarcoma or leukemia in the sample. A method for determining presence of leukemia, lymphoma, head and neck squamous cell carcinoma, or mammary carcinoma in a sample, comprises: assaying the sample for mRNA for MAGE-B2, wherein presence of the mRNA is indicative of possibility of leukemia, lymphoma, head and neck squamous cell carcinoma, or mammary carcinoma in the sample. A method for determining presence of skin carcinoma mammary carcinoma, comprises: assaying a sample for presence of mRNA for MAGE-B1 gene, wherein presence of the mRNA is indicative of possibility of skin carcinoma or mammary carcinoma in the sample.</p> |
